Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass

J Thorac Cardiovasc Surg. 2001 Aug;122(2):365-70. doi: 10.1067/mtc.2001.114938.

Abstract

Background: The bioactive peptide endothelin-1 is elevated during and after cardiopulmonary bypass and exerts cardiovascular effects through its 2 receptor subtypes, endothelin-1A and endothelin-1B. Increased endothelin-1A receptor stimulation after cardiopulmonary bypass can cause increased pulmonary vascular resistance and modulate myocardial contractility. However, whether and to what degree selective endothelin-1A blockade influences these parameters in the postbypass setting is not completely understood.

Objectives: Our objective was to measure left ventricular function and hemodynamics in a porcine model of cardiopulmonary bypass after selective blockade of endothelin-1A.

Methods: Adult pigs (n = 23) underwent 90 minutes of cardiopulmonary bypass and were randomized 30 minutes after bypass to receive a selective endothelin-1A antagonist (TBC 11251, 10 mg/kg; n = 13) or saline vehicle (n = 10).

Results: After bypass and before randomization, pulmonary vascular resistance rose nearly 4-fold, and left ventricular preload recruitable stroke work fell to one third of baseline values (both P <.05). In the vehicle group pulmonary vascular resistance continued to rise, and preload recruitable stroke work remained reduced. However, after endothelin-1A blockade, the rise in pulmonary vascular resistance was significantly blunted compared with that in the vehicle group. Moreover, the reduction in pulmonary vascular resistance with endothelin-1A blockade was achieved without a significant change in systemic perfusion pressures.

Conclusions: The present study demonstrated that increased activity of the endothelin-1A receptor likely contributes to alterations in pulmonary vascular resistance in the postbypass setting. Selective endothelin-1A blockade may provide a means to selectively decrease pulmonary vascular resistance without significant effects on systemic hemodynamics.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Analysis of Variance
  • Animals
  • Cardiopulmonary Bypass*
  • Disease Models, Animal
  • Endothelin-1 / blood
  • Endothelin-1 / drug effects
  • Hemodynamics / drug effects
  • Hemodynamics / physiology
  • Hypertension, Pulmonary / blood
  • Hypertension, Pulmonary / physiopathology
  • Isoxazoles / pharmacology*
  • Pulmonary Circulation / drug effects
  • Pulmonary Circulation / physiology*
  • Receptors, Endothelin / drug effects
  • Receptors, Endothelin / physiology
  • Swine
  • Thiophenes / pharmacology*
  • Vascular Resistance / drug effects
  • Vascular Resistance / physiology*
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Left / physiology*

Substances

  • Endothelin-1
  • Isoxazoles
  • Receptors, Endothelin
  • Thiophenes
  • sitaxsentan